CatalystMarker
Sign in
← board

AMGN

Amgendistress 3/10 · well-funded / low risk
$361.96-1%today-7% from 52w high
amgen.com31,500 employeesFounded 1980Thousand Oaks, CADrug Manufacturers - General
Immunology / Inflammation 1Oncology 1
Lead: Obesity · target PD-1 · est. market ~$15B (approx, global)
Revenue
$8618M
Liquidity
$12038M
Runway
—
Shares 1y
+0%

Price & events

+5.8% over 6M
$321$353$385Jan 26Apr 26Jul 269.2Mdilution: 424B2 offering (2026-02-19)dilution: FWP offering (2026-02-17)dilution: 424B3 offering (2026-02-17)dilution: S-3ASR shelf_registration (2026-02-13)financing: 8-K material_agreement (2026-02-19)catalyst: PHASE1 AMG 355, Pembrolizumab (2026-07-21) — click to opencatalyst: PHASE2 HZN-1116 (2026-04-28) — click to openrating: Guggenheim: Neutral (2026-07-13)rating: UBS: Buy (2026-07-13)rating: Morgan Stanley: Equal-Weight (2026-07-08)rating: Truist Securities: Hold (2026-07-07)rating: Cantor Fitzgerald: Neutral (2026-07-06)rating: Mizuho: Neutral (2026-06-16)rating: Morgan Stanley: Equal-Weight (2026-06-10)rating: Piper Sandler: Overweight (2026-05-14)
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-2.6%
1W
+4.3%
1M
+4.6%
3M
+6.5%
6M
+20.6%
1Y
+15.5%
2Y
+71.0%
5Y
+89.6%
All

Overview

Market Cap
$195.35B
Enterprise Value
$235.20B
Volume
117.81K
52 Week Range
$271 – $388
Total Shares
539.71M
Float Shares
538.22M
Short %
2.39%
% Held by Insiders
0.22%
% Held by Institutions
85.08%
RVOL
0.04x
Beta
0.40

Pipeline stages · 22 programs

Apremilast
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-08-06
Dazodalibep
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-08-19
Xaluritamig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-10-08
Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-10-31
ABP 206, Nivolumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-14
Sotorasib, Panitumumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-17
Tarlatamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12-30
Ocrelizumab (US), Ocrelizumab (EU), ABP 692
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-15
Maridebart cafraglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-21
AMG 509, Abiraterone, Enzalutamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-02-22
Show all 22 programs · 12 more ▾
Inebilizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-13
Romosozumab, Bisphosphonate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-04
Etelcalcetide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-30
Blinatumomab, HyperCVAD
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11-24
Olpasiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03-31
Vitamin D, Calcium
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04-19
ZL-1310, Tarlatamab, Durvalumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-05-21
Pegloticase, Methotrexate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-18
FOLFIRI Regimen, Sotorasib, Panitumumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09-25
Avacopan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09-26
YL201, Tarlatamab, Durvalumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-06-23
HZN-1116
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 72 trials · 70 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-08-06
Estimated 50%
readout ~2026-10-20
Phase 3ApremilastPlaque Psoriasis—active not recruiting
2026-08-19
Estimated 50%
readout ~2026-11-02
Phase 3DazodalibepSjogren's Syndrome—active not recruiting
2026-10-08
Estimated 50%
readout ~2026-11-07
Phase 1XaluritamigProstate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer—active not recruiting
2026-10-22
Estimated 50%
readout ~2027-01-05
Phase 3DazodalibepSjögren's Syndrome (SS)—active not recruiting
2026-10-31
Estimated 50%
readout ~2026-11-30
Phase 1Anvumetostat, Carboplatin, PaclitaxelThoracic Tumors, Non-small Cell Lung Cancer—active not recruiting
Show all 72 trials · 67 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2026-10-31
Estimated 50%
readout ~2026-11-30
Phase 1Anvumetostat, Gemcitabine, Nab-paclitaxelAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers—active not recruiting
2026-10-31
Estimated 50%
readout ~2026-12-15
Phase 2anvumetostatMTAP-deleted NSCLC—active not recruiting
2026-11-30
Estimated 50%
readout ~2027-01-14
Phase 1/2Anvumetostat, Docetaxel, Comparator Anvumetostat Test TabletAdvanced MTAP-null Solid Tumors—active not recruiting
2026-12-14
Estimated 50%
readout ~2027-02-27
Phase 3ABP 234, PembrolizumabEarly-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)—active not recruiting
2026-12-17
Estimated 50%
readout ~2027-01-16
Phase 1Sotorasib, Trametinib, RMC-4630Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation—active not recruiting
2026-12-30
Estimated 50%
readout ~2027-02-13
Phase 2TarlatamabRelapsed/Refractory Small Cell Lung Cancer—active not recruiting
2026-12-31
Estimated 50%
readout ~2027-01-30
Phase 1Tarlatamab, Pembrolizumab, CRS Mitigation StrategiesSmall Cell Lung Carcinoma—active not recruiting
2027-01-15
Estimated 50%
readout ~2027-03-31
Phase 3Ocrelizumab (US), Ocrelizumab (EU), ABP 692Relapsing-remitting Multiple Sclerosis (RRMS)—active not recruiting
2027-01-21
Estimated 50%
readout ~2027-04-06
Phase 3Maridebart CafraglutideObesity—active not recruiting
2027-01-21
Estimated 50%
readout ~2027-04-06
Phase 3Maridebart cafraglutideType 2 Diabetes Mellitus (T2DM), Obesity, Overweight—active not recruiting
2027-01-22
Estimated 50%
readout ~2027-02-21
Phase 1Xaluritamig, GnRH AntagonistProstate Cancer—recruiting
2027-02-22
Estimated 50%
readout ~2027-04-08
Phase 1/2AMG 732Thyroid Eye Disease—recruiting
2027-04-13
Estimated 50%
readout ~2027-05-28
Phase 2InebilizumabNeuromyelitis Optica Spectrum Disorder—recruiting
2027-04-24
Estimated 50%
readout ~2027-05-24
Phase 1TarlatamabExtensive Stage Small Cell Lung Cancer—recruiting
2027-04-27
Estimated 50%
readout ~2027-07-11
Phase 3Maridebart cafraglutideObesity Disease—active not recruiting
2027-05-04
Estimated 50%
readout ~2027-07-18
Phase 3Romosozumab, BisphosphonateOsteogenesis Imperfecta—active not recruiting
2027-06-30
Estimated 50%
readout ~2027-09-13
Phase 3Sotorasib, PembrolizumabNon-Small Cell Lung Cancer (NSCLC)—recruiting
2027-06-30
Estimated 50%
readout ~2027-09-13
Phase 3EtelcalcetideSecondary Hyperparathyroidism—recruiting
2027-07-05
Estimated 50%
readout ~2027-09-18
Phase 3Tarlatamab, DurvalumabExtensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer—active not recruiting
2027-07-31
Estimated 50%
readout ~2027-10-14
Phase 3ABP 938 8 mg, Aflibercept (US) 8 mgNeovascular Age-related Macular Degeneration, nAMD—recruiting
2027-09-29
Estimated 50%
readout ~2027-11-13
Phase 2Maridebart cafraglutideOverweight or Obesity and Elevated Liver Fat—recruiting
2027-09-29
Estimated 50%
readout ~2027-12-13
Phase 3Maridebart cafraglutideObstructive Sleep Apnea—recruiting
2027-09-29
Estimated 50%
readout ~2027-12-13
Phase 3Maridebart cafraglutideObesity, Obstructive Sleep Apnea—recruiting
2027-11-24
Estimated 50%
readout ~2028-01-08
Phase 1/2BlinatumomabB Cell Precursor Acute Lymphoblastic Leukemia—active not recruiting
2028-01-02
Estimated 50%
readout ~2028-02-16
Phase 2Sotorasib, PanitumumabAdvanced Solid Tumors—recruiting
2028-01-03
Estimated 50%
readout ~2028-03-18
Phase 3Maridebart CafraglutideObesity or Overweight—recruiting
2028-01-10
Estimated 50%
readout ~2028-03-25
Phase 3ABP 234, Pembrolizumab (US), Pembrolizumab (EU)Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer—active not recruiting
2028-01-25
Estimated 50%
readout ~2028-04-09
Phase 3ABP 206, NivolumabMelanoma—active not recruiting
2028-01-29
Estimated 50%
readout ~2028-03-14
Phase 2AMG 732Thyroid Eye Disease—recruiting
2028-01-30
Estimated 50%
readout ~2028-02-29
Phase 1XaluritamigMetastatic Castration-resistant Prostate Cancer (mCRPC)—recruiting
2028-03-18
Estimated 50%
readout ~2028-04-17
Phase 1Tarlatamab, AB248Extensive Stage Small Cell Lung Cancer—recruiting
2028-03-21
Estimated 50%
readout ~2028-06-04
Phase 3ApremilastActive Juvenile Psoriatic Arthritis—recruiting
2028-03-27
Estimated 50%
readout ~2028-04-26
Phase 1Xaluritamig, Darolutamide, AbirateroneMetastatic Hormone-sensitive Prostate Cancer (mHSPC)—recruiting
2028-03-31
Estimated 50%
readout ~2028-06-14
Phase 3OlpasiranAtherosclerotic Cardiovascular Disease—active not recruiting
2028-04-18
Estimated 50%
readout ~2028-05-18
Phase 1AMG 410, Pembrolizumab, PanitumumabKRAS Altered Advanced or Metastatic Solid Tumors—recruiting
2028-04-19
Estimated 50%
readout ~2028-07-03
Phase 3Vitamin D, CalciumOsteogenesis Imperfecta—recruiting
2028-05-21
Estimated 50%
readout ~2028-06-20
Phase 1ZL-1310, Tarlatamab, DurvalumabSmall Cell Lung Cancer—recruiting
2028-06-15
Estimated 50%
readout ~2028-08-29
Phase 3OlpasiranCardiovascular Disease—recruiting
2028-06-18
Estimated 50%
readout ~2028-09-01
Phase 3Pegloticase, MethotrexateUncontrolled Gout—recruiting
2028-06-28
Estimated 50%
readout ~2028-07-28
Phase 1AMG 436Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)—recruiting
2028-06-30
Estimated 50%
readout ~2028-09-13
Phase 3Maridebart cafraglutideHeart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity—recruiting
2028-06-30
Estimated 50%
readout ~2028-09-13
Phase 3Maridebart CafraglutideAtherosclerotic Cardiovascular Disease, Overweight, Obesity—recruiting
2028-07-21
Estimated 50%
readout ~2028-09-04
Phase 2Inebilizumab, BlinatumomabSystemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis—recruiting
2028-08-28
Estimated 50%
readout ~2028-09-27
Phase 1Tarlatamab, Carboplatin, EtoposideExtensive Stage Small Cell Lung Cancer—active not recruiting
2028-09-25
Estimated 50%
readout ~2028-12-09
Phase 3FOLFIRI Regimen, Sotorasib, PanitumumabMetastatic Colorectal Cancer—recruiting
2028-09-26
Estimated 50%
readout ~2028-12-10
Phase 3AvacopanVasculitis—recruiting
2028-12-05
Estimated 50%
readout ~2029-01-19
Phase 1/2BlinatumomabRelapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia—active not recruiting
2029-01-02
Estimated 50%
readout ~2029-03-18
Phase 3Xaluritamig, Abiraterone, EnzalutamideMetastatic Castration-resistant Prostate Cancer—active not recruiting
2029-01-04
Estimated 50%
readout ~2029-03-20
Phase 3Tarlatamab, Durvalumab, CarboplatinSmall-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer—recruiting
2029-01-31
Estimated 50%
readout ~2029-04-16
Phase 3EtelcalcetideSecondary Hyperparathyroidism, Chronic Kidney Disease—recruiting
2029-02-09
Estimated 50%
readout ~2029-03-26
Phase 2TarlatamabSmall Cell Lung Cancer (SCLC)—active not recruiting
2029-09-07
Estimated 50%
readout ~2029-11-21
Phase 3Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimenNewly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)—active not recruiting
2029-12-11
Estimated 50%
readout ~2030-02-24
Phase 3DazodalibepSjögren's Syndrome—recruiting
2030-01-07
Estimated 50%
readout ~2030-03-23
Phase 3Xaluritamig, Abiraterone acetate, DocetaxelMetastatic Castration-resistant Prostate Cancer—recruiting
2030-02-07
Estimated 50%
readout ~2030-04-23
Phase 3ApremilastBehçet Disease—recruiting
2030-03-13
Estimated 50%
readout ~2030-04-27
Phase 2InebilizumabGeneralized Myasthenia Gravis—recruiting
2030-03-22
Estimated 50%
readout ~2030-04-21
Phase 1AMG 509, Abiraterone, EnzalutamideProstate Cancer—recruiting
2030-04-20
Estimated 50%
readout ~2030-07-04
Phase 3TarlatamabLimited Stage Small Cell Lung Cancer, Small Cell Lung Cancer—active not recruiting
2030-05-10
Estimated 50%
readout ~2030-07-24
Phase 3Blinatumomab, HyperCVADPhiladelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia—not yet recruiting
2030-05-26
Estimated 50%
readout ~2030-06-25
Phase 1XaluritamigEwing Sarcoma—recruiting
2031-06-10
Estimated 50%
readout ~2031-07-25
Phase 2InebilizumabImmunoglobulin G4-related Disease—not yet recruiting
2031-06-23
Estimated 50%
readout ~2031-07-23
Phase 1YL201, Tarlatamab, DurvalumabSmall Cell Lung Cancer—active not recruiting
2031-07-30
Estimated 50%
readout ~2031-10-13
Phase 3InebilizumabAutoimmune Hepatitis, AIH—not yet recruiting
2031-10-20
Estimated 50%
readout ~2032-01-03
Phase 3OlpasiranCardiovascular Disease—recruiting
2036-03-17
Estimated 50%
readout ~2036-05-31
Phase 3ApremilastBehçet's Disease, Juvenile Psoriatic Arthritis—recruiting
2026-07-21
Estimated 50%
readout ~2026-08-20
final ~2027-01-31
Phase 1AMG 355, PembrolizumabAdvanced Solid Tumors77active not recruiting
2026-04-28
Phase 2HZN-1116Sjogren's Syndrome209terminated

Catalyst news & presentations · 1

Approved drugs (14)

  • OTEZLAAPREMILAST2025 · Prescription
  • PAVBLUAFLIBERCEPT-AYYH2024 · Prescription
  • BKEMVECULIZUMAB-AEEB2024 · Prescription
  • IMDELLTRATARLATAMAB-DLLE2024 · Prescription
  • WEZLANAUSTEKINUMAB-AUUB2023 · Prescription
  • WEZLANAUSTEKINUMAB-AUUB2023 · Prescription
  • LUMAKRASSOTORASIB2021 · Prescription
  • REPATHAEVOLOCUMAB2021 · Prescription
  • RIABNIRITUXIMAB-ARRX2020 · Prescription
  • AVSOLAINFLIXIMAB-AXXQ2019 · Prescription

Capital structure — dilution & financing

Shares out: 539,708,274 · 3 offerings/1y · 0 PIPEs
  • 2026-02-198-Kmaterial_agreement
  • 2026-02-19424B2offering
  • 2026-02-17424B3offering
  • 2026-02-17FWPoffering
  • 2026-02-13S-3ASRshelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $357 (-1% upside) · 29 analysts
  • 2026-07-13GuggenheimNeutral
  • 2026-07-13UBSBuy
  • 2026-07-08Morgan StanleyEqual-Weight
  • 2026-07-07Truist SecuritiesHold
  • 2026-07-06Cantor FitzgeraldNeutral
  • 2026-06-16MizuhoNeutral

Competitors — PD-1

  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
  • BEIGFBeOne Medicines Ltd.$31.7B · D1
  • NCNANuCana plc$28.3B · D2
  • EXELEXELIXIS, INC.$13.8B · D0
  • IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
  • CGEMCullinan Therapeutics, Inc.$1.1B · D1
  • REPLReplimune Group, Inc.$906M · D2
  • ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
  • BCABBioAtla, Inc.$107M · D8
  • IOBTQIO Biotech, Inc.$71,949 · D5

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.